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INTRODUCTION 
It is sometimes assumed in evaluating data from some pharmacokinetic 
and pharmacogenetic studies that the half-life of elimination of a drug which 
is appreciably or essentially completely metabolized by man is essentially 
a constant for a given individual subject. I have run a large number of care- 
fully controlled crossover studies in so-called normal subjects during the 
past I0 years. The impression gained from these studies is that there is 
appreciable intrasubject variation in half-lives of elimination. The mag- 
nitude of intrasubject and intersubject variation in half-lives of elimination 
is apparently drug specific and needs to be checked out with each drug. 
Some of the results obtained over the past 10 years are described below. 
CLINDAMYCIN 
Clindamycin is a semisynthetic antibiotic, namely, 7(S)-chloro-7- 
deoxylincomycin hydrochloride hydrate. Novak et al. (1) reported serum 
concentrations of clindamycin in ten adult male volunteers following intra- 
muscular administration of 1, 1.5, and 2 ml doses of a sterile solution of the 
hydrochloride salt containing a label of 100rag of base equivalent per 
milliliter. The half-life of each subject following each treatment was estimated 
from those terminal serum concentrations which appeared to be randomly 
distributed about a straight line when the serum concentrations were plotted 
on semilogarithmic graph paper. The half-life (tl/2) was estimated from 
equation 2 following least-squares regression analysis employing equation 1 : 
l n C = l n C  o - K t  (1) 
tl/z = 0.693/K (2) 
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Table I. Half-Lives of Elimination of Clindamycin in Ten Normal Male Adult Volunteers 
1 ml dose 1.5 ml dose 2.0 ml dose 
Subject Dose (mg/kg) t 1/2 (hr) Dose (mg/kg) t l/z (hr) Dose (mg/kg) t 1/2 (hr) 
1 1.86 3.20 2.79 4.02 3.72 3.50 
2 1.07 5.20 1.60 3.92 2.13 4.58 
3 1.71 2.95 2.56 4.04 3.42 3.56 
4 1.54 2.53 2.31 2.88 3.08 4.73 
5 1.25 6.68 1.87 6.24 2.50 6.34 
6 1.73 3.07 2.60 3.52 3.47 3.49 
7 1.35 7.06 2.03 4.38 2.70 4.37 
8 1.25 5.14 1.87 5.19 2.50 6.83 
11 1.31 7.74 1.96 4.87 2.61 5.97 
12 1.16 4.68 1.74 5.53 2.32 6.66 
Results are shown in Table  I. It may be seen that there is considerable  intra- 
subject var ia t ion in the t i /2  values. The analysis of variance of the half-lives 
shown in Table  I is given in Table  II. The failure of the t rea tment  mean  
square to be significant suggests strongly that the t l /2  est imat ion was not  
influenced by the dose of c l indamycin  administered.  There was a significant 
intersubject  var ia t ion in t l / 2 ,  as evidenced by the significant mean square 
for subjects. The residual mean  square is a measure of intrasubject  var ia t ion 
in the t~/z plus unexpla ined error. The coefficient of var iat ion calculated by 
equa t ion  3 below was 19.9%. 
In another  study reported by Wagner  e t  al.  (2), 150 mg doses of clinda- 
mycin base equivalent  were adminis tered orally as the hydrochlor ide  salt in 
both tablets and  capsules in a 12 subject crossover study. Half-lives could be 
estimated in ten subjects from serum concent ra t ions  measured by an ex- 
t rac t ion-microbio log ica l  assay. Ten half-lives estimated following admin-  
is trat ion of the capsule averaged 2.55 hr, with a s tandard  deviat ion of 
0.94 hr. Ten  half-lives estimated following admin is t ra t ion  of the tablet 
averaged 2.21 hr, with a s tandard  deviat ion of 0.48 hr. The difference be- 
tween these averages was not significant (p > 0.10), suggesting strongly that 
cont inued  absorp t ion  from the dosage forms was not  biasing one set of 
Table II. Analysis of Variance of Half-Lives of Elimination of Clindamycin Shown in Table I 
Source of 
variation df SS MS F P 
Total 29 58.389 - -  - -  - -  
Treatments 2 1.539 0.770 0.862 P > 0.25 
Subjects ~9 40.779 4.531 5.07 0.005 > P > 0.001 
Residual 18 16.072 0.893 - -  
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Fig. 1. A plot of the half-life ofcl indamycin after oral 
administrat ion from serum concentration data ob- 
tained during week 2 (phase II) against the half-life 
obtained during week 1 (phase I) for the same nine 
subjects. The plot shows that the ratio (half-life 
during week 2)/(half-life during week 1) varied from 
0.67 to 1.33 with an average of 1.0. 
half-lives more than the other. In Fig. 1, the half-life estimated from the 
week 2 (phase II) data is plotted against the half-life estimated from the 
week l (phase I) data for nine subjects. The intrasubject variation in tt/2 is 
obvious. 
The overall mean tl/2 of clindamycin following intramuscular admin- 
istration (data in Table I) is 4.76 hr. The overall mean tl/2 of clindamycin 
following oral administration is 2.38 hr (2). The slope of the plot of area under 
the serum concentration vs. mg/kg dose following intramuscular admin- 
istration is 10.3 (1). The average area under the serum concentration curve 
following 150 mg oral doses as tablets or capsules is 10.9 (#g/ml) x hr in a 
panel with average body weight of 75.3 kg, giving a ratio of 5.48 (yg/ml) 
x hr per 1 mg/kg clindamycin base administered. Hence the doubling of the 
half-life of clindamycin when given intramuscularly compared with orally is 
reflected in an approximate doubling of the area (since 10.3/5.48 = 1.9). 
Hence the "route of administration" effect can be very important with certain 
drugs. 
WARFARIN 
Wagner et al. (3) listed plasma concentrations of warfarin, measured by 
both a thin layer chromatographic method and an extraction method, in six 
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Table 111. Half-Lives of Warfarin in Hours Estimated from Terminal Plasma Concentrations" 
Measured by Modified O'Reilty Assays and TLC Assays on Same Samples b 
Treatment A Treatment B 
(five 5 mg tablets) (one 25 mg tablet) 
Normalized Normalized 
difference ~ difference ~ 
Subject TLC O'Reilly (%) TLC O'Reiliy (%) 
1 33.6 28.8 -15.4 35.1 34.3 -2.3 
2 24.6 27.1 9.7 29.9 29.7 -0,7 
3 34.8 47.2 30.2 42.7 55.0 25.2 
4 26,8 33.7 22.8 29.5 26.2 - 11.8 
5 40.8 31.1 -27.0 41.4 56.9 31.5 
6 - -  - -  33,7 34.5 2.3 
6a 49.5 44.2 - 1 1 . 3  - -  - -  - -  
Averages 35,0 d 35.M 1.5 35X 39.4 e 7.4 
Normalized 
TLC O'Reilly difference (%) 
Overall averages 35.2: 37.4: 4,5 
a Half-lives were estimated by obtaining the slope of line, by the method of least squares, when 
In Cp is plotted vs. t, and dividing the absolute value of the slope into 0.693. Only plasma con- 
centrations corresponding to times equal to or greater than 24 hr were employed. 
b Data plotted in Fig. 4 of Welling et al. (6). 
c Normalized difference equals half-life from O'Reilly assays minus half-life from TLC assays 
divided by average half-life from O'Reilly and TLC assays x I00. 
'~ Difference in averages is not significant by paired t-test (t = 0.097~ p > 0.25). 
e Difference in averages is not significant by paired t-test (t = 1.27, p > 0.10). 
: Difference in averages is not significant by paired t-test ( f  = 0.95. p > 0.25). 
n o r m a l  v o l u n t e e r s  fo l l owing  ora l  a d m i n i s t r a t i o n  o f  25 mg  doses  o f  war fa r in  
s o d i u m  as five 5 m g  tab le t s  a n d  one  25 mg  table t .  Hal f - l ives  of  war fa r in  
e s t i m a t e d  f r o m  these  p l a s m a  c o n c e n t r a t i o n s  were  s u m m a r i z e d  by W a g n e r  
(4) a n d  a re  p r e s e n t e d  aga in  in T a b l e  III .  T h e  m o d i f i e d  O ' R e i l l y  (ex t rac t ion)  
assay  m e t h o d  g a v e  a l o n g e r  half-l ife in six trials,  b u t  the  T L C  assay  g a v e  a 
l o n g e r  half-l ife in exact ly  six o t h e r  trials. T h e  d i f ference  in a v e r a g e  half- l ives  
o b t a i n e d  by the  two  m e t h o d s  was no t  s ignif icant .  T h e  s tat is t ics  p r e s e n t e d  in 
T a b l e  I l l  a lso  ind ica t e  tha t  the  p a r t i c u l a r  tab le ts  a d m i n i s t e r e d  d id  no t  
affect the  half- l ives  ob t a ined .  T h e r e  is i n t r a sub j ec t  v a r i a t i o n  in half- l ives,  
however .  Th is  is e m p h a s i z e d  fu r ther  by the  da t a  in T a b l e  IV, t aken  f rom 
W a g n e r  (5). Th is  tab le  lists half- l ives  of  war fa r in  in four  n o r m a l  v o l u n t e e r s  
w h o  t o o k  par t  in two  different  c r o s s o v e r  s tudies  in which  war fa r in  was  d o s e d  
ora l ly  as c o m m e r c i a l  t ab le t s  of  different  types.  T h e  half- l ives  r e c o r d e d  in 
T a b l e  IV were  no t  s igni f icant ly  c o r r e l a t e d  with  the  dose  n u m b e r ,  the  d o s i n g  
d a y  n u m b e r ,  o r  the  d o s e  a d m i n i s t e r e d .  T h e r e  was  a l so  s t r o n g  p h a r m a c o -  
k ine t ic  e v i d e n c e  that  a b s o r p t i o n  of  war fa r in  h~d ceased, s o m e t i m e  before  the  
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Table IV. Warfarin Half-Lives Estimated from Terminal Plasma Concentrations for Four 
Subjects Common to Two Clinical Studies 
Half-life (hr) 
Study No. 1 Study No. 2 
Subject Phase I Phase II Phase I Phase II Phase III C.V. (%) 
B 26.6" 33.7 ~ 51.3 c 46.9 ~ 42.0 c 24.9 
C r 47.2 b 55.0" 59.9 c 34.1 c 34.Y 25.4 
C h 56.9" 31. lb 52.1 c 56.8 c 74.5 ~ 28.6 
R 28.8 b 34.3 a 59.9 c 42.7 r 76.8 ~ 40.6 
Dose No. 1 2 3 4 5 - -  
Dosing day No. 1 22 64 85 106 - -  
a One 25 mg tablet. 
b Five 5 mg tablets. 
c Two 5 mg tablets. 
first sampling time which was used to estimate the half-life. In these studies, 
intrasubject variation in half-life was approximately the same as inter- 
subject variation in half-life. The coefficients of variation listed in the last 
column of Table IV give an indication of the magnitude of intrasubject 
variation of the half-life of warfarin. 
E P H E D R I N E  
Half-lives of ephedrine in man, estimated from the urinary excretion 
data of Welling et al. (6), and summarized by Wagner (5), are reproduced in 
Table V. An analysis of variance of the data in Table V is given in Table VI. 
Table V. Intrasubject Variation in Half-Life of Ephedrine Following Single Oral Doses 
of 25 mg Ephedrine Sulfate to Three Adult, Nonsmoking Male Volunteers 
Subject 
Treatment A" Treatment B b Treatment C c 
tl/2 No. 1 d t l /2 No. 2 e t l /2 No. 1 t~/2 No. 2 tl/2 No, 1 t~/2 No. 2 
1 7.46 7.17 7.35 5.33 5.14 5.27 
2 5.35 5.93 6.71 5.27 5.01 4.94 
3 5.15 5.25 6.08 5,92 5.69 5.77 
"Treatment A was Ephedrine Sulfate Syrup (Eli Lilly & Co.). 
b Treatment B was Ephedrine Sulfate Capsules 25 mg (3 gr) (Eli Lilly & Co.). 
c Treatment C was Ephedrine Sulfate Capsules 25 mg (~ gr) (American Pharmaceutical 
Co.). 
d t l /2  No. 1 is 0.693/fl, where fl was obtained by fitting all data of each subject on each 
treatment to the two-compartment open model with first-order absorption. 
tl/2 No. 2 was obtained from terminal excretion rates only by the method of least 
squares applied to In (excretion rate) vs. time. 
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T a b l e  VI.  Ana lys i s  o f  V a r i a n c e  o f  Ha l f -L ives  o f  E p h e d r i n e  S h o w n  in T a b l e  V 
Source  o f  
va r i a t i on  df  SS M S  F P 
T o t a l  17 11.487 - -  - -  
T r e a t m e n t s  2 2.428 1.214 2.22 0.25 > P > 0.10 
Subjec ts  2 1.981 0.991 1.82 0.25 > P > 0.10 
M e t h o d  of  
o b t a i n i n g  tl/2 I 0 .530 0.530 0.97 P > 0.25 
Res idua l  12 6.547 0.546 - -  - -  
The mean squares for treatments, subjects, and methods of obtaining the 
t~/2 values are all not significant. The residual mean square is 55 % of the 
between-subject  mean square. The residual mean square is a measure of 
intrasubject and unexplained variation. The coefficient of variation, cal- 
culated from the grand mean and the residual mean square (RMS) by 
equation 3, 
C.V.(%) = ( ,~-MS/grand mean) x 100 (3) 
is 12.7 %. 
LINCOMYCIN 
Wagner et al. (7) reported on half-',ves of the antibiotic lincomycin 
observed in repetitive studies on the same subjects. These data were extended 
and summarized by Wagner (5) and are reproduced as Table VII. After 
solution and capsule treatments, the median half-lives were, study II, 4.38 
and 4.55 ; study III, 4.87 and 4.36 hr, respectively. This and other analysis of 
the data indicated that the dosage form per se was not influencing the half- 
life estimated, as would be expected if there were absorption still occurring 
when the half-lives were estimated. The half-|ire of lincomycin in some 
subjects is quite reproducible from study to study, as can be seen by the 
data for subjects B and P in Table VII. However, other subjects, such as H 
and E, show considerable intrasubject variation in half-life. 
ETHOSUXIMIDE 
Buchanan et al. (8) administered ethosuximide in syrup and capsule 
dosage forms to the same four children at different times. Elimination half- 
lives were estimated from terminal plasma concentrations. Their data are 
summarized in Table VIII. The half-lives were quite reproducible in subjects 
1, 2, and 4 but not in subject 3. 
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Table  VII.  In t rasub jec t  Var i a t ion  in Half-Life a of L incomyc in  O b s e r v e d  in Repet i t ive  Studies  
in the Same Six Adu l t  Ma le  Subjects  After O r a l  A d m i n i s t r a t i o n  of L i n c o m y c i n  H y d r o c h l o r i d e  
in Rap id ly  Disso lv ing  Capsu les  or in Aqueous  Solu t ion  
Subject  
Da te  
Study Da te  H E C K B P med ian  
III  
2/18/64 - -  6.13 b - -  5.36 b - -  4.26 b 5,36 
2/25/64 13.8 b - -  5.37 - -  4.47 b - -  5.37 
3/24/64 4.00 c 4.2 c 4.43 5.22 5.22 4.51 c 4.47 
3/31/64 5.90 b 5.62 4.80 c 4.55 c 4.19 c 4.55 b 4.68 
5 / i9 /64  7.86 a 8.43 e 5.15 e 4.2M 4.59 e 4.47 d 4.87 
5/26/64 9.69 e 4.90 a 4.22 d 4.09 4.18 d 4.14 e 4.20 
M e d i a n  7.86 5.62 4.80 4.55 4.47 4.51 4.60 
E q u a t i o n s  1 and  2 were 
were used. 
b F o r m u l a t i o n  1 (median  
c F o r m u l a t i o n  2 (median  
a F o r m u l a t i o n  3 (median  
e F o r m u l a t i o n  4 (median  
employed .  Usua l ly  the 8, 10, 12, and  14 or the 10, 12, and  14 hr  poin ts  
half-life 5.29 hr). 
half-life 4.38 hr). 
half-life 4.36 hr). 
half-life 4.87 hr). 
ETHANOL 
Vesell et al. (9) measured apparent zero-order rates of ethanol metab- 
olism in fraternal and identical twins only once in each subject and found 
that the interpair differences were significantly greater in fraternal twins 
than in identical twins. They stated that their "investigation did not test the 
possibility of day-to-day variations of alcohol metabolism within the same 
subject," yet they calculated that the contribution of hereditary to individual 
differences in ethanol metabolism was 0.98 out of 1.0. In the same paper, 
they did report apparent zero-order rates of ethanol metabolism in six male 
volunteers before and after ingestion of 1 ml of 95 % alcohol per kilogram 
Table  VIII .  Half-Lives  of E t h o s u x i m i d e  in the Same F o u r  Ch i ld ren  as 
Repor ted  by B u c h a n a n  et  al. (8) 
Half-life (hr) 
Subject  Body weight  (lb) Syrup  Capsu le  
1 30.0 24.8 25.7 
2 40.0 31.8 30.0 
3 37.0 37.3 26.9 
4 28.5 31.6 30.1 
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Table IX, Apparent Zero-Order Rates of Ethanol Metabolism in Six Male 
Volunteers Before and After Chronic Alcohol Administration ~ 
Apparent zero-order rate [mg/(ml • hr)] 
Subject Before After Percent change 
A.M. 0,186 0.200 +7.5 
C.G. 0.203 0.255 + 25.6 
EW. 0.200 0.195 -2 .5  
G.P. 0.223 0.180 - 19.3 
M.M. 0.122 0.235 + 92.6 
R.G. 0.192 0.180 -6 .3  
Average 0,188 ~ 0.208 b 
C,V. (%) 18.4 14.8 
One milliliter 95 ~o ethanol per kilogram body weight per day for 21 days 
as reported by Vesell et al. (9). 
b Paired t-test gave t = 0.88 (p > 0.25). 
of body weight per day for 21 days. These data are summarized in Table IX. 
The mean rates of 0.188 and 0.208 were not significantly different by a paired 
t-test, but there were relatively large differences in the "before" and "after" 
rates in three of the six subjects, as indicated by the last column in Table IX. 
It should be pointed out that the formula used by Vesell et al. (9) to 
estimate the hereditary component assumes no intrasubject variation in 
clearance rate of a drug. It is the author's opinion that such pharmacogenetic 
studies should include repeated measurements in the same subjects and use 
of a more complicated formula for estimating the hereditary component. 
Wagner and Patel (10) reported capillary blood ethanol concentrations 
measured in the same normal adult volunteer when he was given three 
different doses of ethanol in five different controlled trials. The estimated 
volume of distribution of ethanol had a coefficient of variation of 12~o. 
However, the estimated apparent zero-order rates of ethanol metabolism 
had a coefficient of variation of 26.7 ~o. They also estimated V,, and K,, 
values by direct computer fitting of the terminal alcohol blood concentrations 
to the integrated form of the Michaelis-Menten equation. The estimated 
V,, values had coefficients of variation of 50.5 and 45.3 ~o, and the estimated 
K m values had coefficients of variation of 98.3 and 97.3 ~, depending on 
which estimates were included. It should be particularly emphasized that 
the intrasubject coefficient of variation of 26.7 ~o for the apparent zero-order 
rate of ethanol metabolism in men in this study was larger than the inter- 
subject coefficients of variation of 18.4 and 14.8~ calculated from the 
before and after data of Vesell et al. shown in Table IX. Also, the standard 
deviation calculated from the differences (after minus before) from the data 
in Table IX is 0.0554 and the grand mean is 0.198, giving a coefficient of 
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v a r i a t i o n  of 28.0 %. This  va lue  agrees  qu i te  well wi th  the va lue  of 26.7 % 
ca lcu la t ed  by  W a g n e r  a n d  Pate l  (10). T h u s  these da ta  t end  to ind ica t e  tha t  
in t rasubjec t  v a r i a t i o n  of the a p p a r e n t  z e ro -o rde r  ra te  of e t h a n o l  m e t a b o l i s m  
is g rea te r  t h a n  the  in tersubjec t  va r i a t i on .  T h i s  does  n o t  a p p e a r  to be  theo-  
ret ical ly  s o u n d  for a large p o p u l a t i o n ,  b u t  for the  smal l  a m o u n t  of  da t a  
ava i l ab l e  one  o b t a i n s  tha t  answer .  
In s u m m a r y ,  there  is ev idence  that  with m a n y  d rugs  i n t r a s u b j e c t  
v a r i a t i o n  in e l i m i n a t i o n  rate  c o n s t a n t s  a n d  half- l ives of d rugs  is a p p r e c i a b l e  
a n d  c a n n o t  be  ignored .  
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